European Urology Focus
Издатель: Elsevier · ISSN 2405-4569 · 97 статей
- Reply to Flavio L. Heldwein et al’s Letter to the Editor re: Little M, Wolstenholme J, Landeiro F, Marian IR, Williams R, Francisco Lopez J, et al. Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study. Eur Urol Focus 2026;12:227–36
- First-in-clinical Evaluation of Dual Contrast-enhanced Ultrasound-guided PCNL: A Multicenter Randomized Trial Versus Fluoroscopy
- Editorial Board
- Contents
- Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001
- Clinical Predictors of Local and Atypical Site Recurrence After Partial and Radical Nephrectomy for Localized Renal Cell Cancer
- The Complex Relationship Between Volume and Outcome of AMS 800 Implants in the SATURN Database
- Radioligand Therapy of the Prostate – the Sky Is the Limit?
- PSMA Radioligand Therapy: Success and Limitations to Date
- Success and Limitations of PSMA RLT : The Nuclear Medicine View
- Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update
- ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT
- Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
- Practical Clinical Consultation Guide to Radioligand Therapy in Prostate Cancer
- Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide
- How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?
- How Will PSMAddition Impact the Management of Prostate Cancer?
- New Paradigms in Theranostics of Prostate Cancer: The Rise of α-Emitters and Next-generation Targets
- Early-access Use of Radioligand Therapy in Prostate Cancer
- Radioligand Therapy Hormone Combinations and the ENZA-p Trial
- Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial
- PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?
- Radioligand Therapy (RLT) in France
- NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer
- Prostate Cancer Working Group 4 Recap
- Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis
- Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model
- Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?
- Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography–positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial
- Long-term Functional Outcomes and Decision Regret after Robot-assisted Radical Prostatectomy: An Experienced Surgeon Series